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• Neuronal damage and loss are the pathological substrate of permanent disability in various 
acute and chronic neurologic disorders. 
• Levels of neurofilament proteins rise upon neuroaxonal damage in cerebrospinal fluid (CSF) 
and in the blood. 
• 1st generation (immunoblot) and 2nd generation (enzyme-linked immunosorbent assay) 
neurofilament assays only captured the tip of the ice-berg in disease. 
• 3rd generation (electrochemiluminescence) and 4th generation (single molecule array) 
assays permithighly sensitive longitudinal detection of blood neurofilament levels even in 
mild disease and from normal controls. [Au: Edited to reduce key point to word limit (30 
words). OK?]  
• Multicentre studies are underway to consolidate neurofilaments as biomarkers that reflect 
brain tissue damage, enabling longitudinal monitoring of disease activity and drug effects 
in clinical trials in neurological diseases. [Au: Edited to reduce key point to word limit (30 
words). OK?] 
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Abstract: 
[Au: Most of my edits to the abstract have been made to reduce the length - the limit is ~200 
words, and the original was 240. Please check that you are happy with how it reads and that no 
crucial information has been removed.]  
Neuroaxonal damage is the pathological substrate of permanent disability in various neurological 
disorders. Reliable quantification and longitudinal follow-up of such damage is important for 
assessing disease activity, monitoring treatment responses, facilitating treatment development 
and prognostic purposes. The neurofilament proteins have promise in this context because their 
levels rise upon neuroaxonal damage not only in the CSF, but also in  blood, and they indicate 
neuroaxonal injury independent of causal pathways. First-generation (immunoblot) and second-
generation (enzyme-linked immunosorbent assay) neurofilament assays were of limited 
sensitivity. Third-generation (electrochemiluminescence) and especially fourth-generation (single 
molecule array) assays enable reliable measurement of neurofilaments throughout the range of 
concentrations found in blood samples. This technological advancement has paved the way to 
investigate neurofilaments in a range of neurological disorders. Here, we review what is known 
about the structure and function of neurofilaments, discuss analytical aspects and knowledge of 
age-dependent normal ranges of neurofilaments and provide a comprehensive overview of 
studies on neurofilament light as a marker for axonal injury in different neurological disorders, 
including multiple sclerosis, neurodegenerative dementia, stroke, traumatic brain injury, 
amyotrophic lateral sclerosis and Parkinson disease. We also consider work needed to explore the 
value of this axonal damage marker in managing neurological diseases in daily practice. 
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[H1] Introduction 
Neuroaxonal damage and loss are the pathological substrate of many acute and chronic 
neurological disorders that result in accrual of permanent disability. [Au: Edited to avoid 
repetition. OK?] The ability to readily detect and follow such damage would be a great advantage 
in the assessment of disease activity, monitoring of treatment responses and prognosis. [Au: 
Edited for flow. OK?] Therefore, a biomarker that accurately reflects neuroaxonal injury would be 
invaluable for reaching individual therapeutic decision and measuring drug effects in clinical trials. 
Attempts to discover such a biomarker have involved investigation of several avenues, [Au: 
Beginning of the previous sentence edited to make clear that the avenues relate to the 
biomarker. OK?] from cerebrospinal fluid (CSF) proteins to MRI, magnetic resonance spectroscopy 
[Au: Changed to group imaging techniques together. OK?] and metabolic imaging, and have 
provided different insights with different limitations. 
Neurofilaments [Au: We prefer not to abbreviate one-word terms, so I think it’s best to 
not use the abbreviation for neurofilament when it’s used alone, but use the abbreviations for 
NfL, NfM and NfH. OK?] are gaining increasing attention as candidate biomarkers of neuroaxonal 
injury [Au: From here to the end of the paragraph, I have rearranged the information so that it’s 
clear that it’s the combination of the specificity and abnormal levels in CSF and serum that 
makes neurofilaments so attractive as biomarkers. Please check you are happy with how this 
reads.] because they are abundant structural scaffolding proteins that are exclusively expressed in 
neurons and that reach pathological levels as a result of axonal damage in neurodegenerative, 
inflammatory, vascular and traumatic diseases not only in the CSF, but also in serum. The 
specificity of neurofilaments in terms of cellular source and indication of pathomechanisms means 
they are highly specific for neuronal cell damage and eventual neuronal cell death, offering a key 
advantage over other possible biomarkers. 
Many, if not all, pathological processes that cause axonal damage release neurofilament 
proteins into the extracellular fluid, CSF and peripheral blood, depending on the extent of damage. 
High levels of neurofilaments, [Au: Addition of “high levels of” OK?] therefore, are general 
indicators of axonal damage irrespective of its cause and any clinical diagnosis, and blood levels of 
neurofilaments are useful for monitoring and prediction of progression in various acute and 
chronic neurological diseases and for assessing the efficacy and/or toxicity of treatment. 
Until recently, measurements of the most promising of the neurofilament proteins, neurofilament 
light levels in patients with neurological disorders could only be performed with CSF samples, 
mainly because assay sensitivity was insufficient for reliable quantification of neurofilament light 
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levels in the blood. Several studies of CSF [Au: Addition of “of CSF” OK, to relate to the previous 
sentence more clearly?] have demonstrated that levels of neurofilament proteins are increased in 
a wide range of neurological diseases1. However, given that lumbar puncture is a relatively 
invasive procedure, longitudinal analyses have been rare and not performed systematically. For 
the same reasons, neurofilaments have rarely been measured in diseases in which diagnostic 
lumbar punctures are infrequently indicated. Neurofilament levels in the blood can be quantified 
with enzyme-linked immunosorbent assay (ELISA)2, 3 and more-sensitive 
electrochemiluminescence (ECL) assay technology in many different diseases4, 5, but neither 
technique can detect small, disease-related changes. Only the introduction of single molecule 
array (SiMoA) [Au: This format has been used by other Nature journals for this abbreviation] 
assays has enabled reliable detection of neurofilament light proteins in blood samples across the 
whole range of concentrations, including those in healthy individuals6-8. Consequently, the past 
2 years have witnessed a surge in the number of publications on neurofilament blood levels in a 
broad range of neurological disorders. 
In this Review, we provide background on the structure and function of neurofilaments, 
consider the analytical aspects of neurofilament measurements and discuss current knowledge on 
age-dependent normal ranges of neurofilament concentrations. We also review the main 
neurological disorders in which neurofilament measurements could play a role in research or 
clinical settings, and highlight aspects that need to be addressed in future studies.  
 
[H1] Neurofilaments — structure and function [Au: Heading shortened to fit our character limits. 
OK?]  
Neurofilaments are classified as intermediate filaments according to their diameter (~10 nm), 
which is between that of actin filaments (6 nm) and myosin filaments (15 nm). Neurofilament 
heavy chain (NfH, 111 kDa), [Au: Molecular weights added here to avoid the need for repetition 
of the subunits later in the paragraph. OK?] neurofilament medium chain (NfM, 102.5 kDa), 
neurofilament light chain (NfL, 61.5 kDa) and α-internexin (55.4 kDa) belong to the class IV 
intermediate filaments, and peripherin (53.7 kDa) is a class III intermediate filament (Fig. 1). The 
molecular weights are higher in vivo owing to an abundance of negatively charged amino acids 
(glutamic acids) in their sequences and to post-translational modifications11. [Au: Statement 
about molecular weights in vivo moved to here to avoid it being disconnected from the 
molecular weights after they have been moved to the previous sentence. OK?] 
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The neurofilament proteins [Au: Correct, or do you did you mean that class III and IV 
intermediate filaments contain intrinsically unstructured regions?] contain intrinsically 
unstructured regions. One key feature of these unstructured regions is that a high proportion of 
residues are lysine9, 10; [Au: Additions for clarity. OK?] lysine and serine are the dominant amino 
acids in the neurofilament tail domain9. A relatively conserved, central α-helical rod region, a short 
variable head domain at the amino-terminal end, and a tail of highly variable length at the 
carboxy-terminal end are highly characteristic for the Nf protein subunits11 (Fig. 1). [Au: Subunit 
list deleted to avoid repetition of what is above. OK?] The head domain contains serine and 
threonine residues and O-linked glycosylation and phosphorylation sites. The tail domain contains 
abundant glutamic and lysine-rich stretches of variable length with multiple serine 
phosphorylation sites. The central rod domain contains hydrophobic repeats that facilitate 
formation of coil-to-coil dimers. 
Formation of neurofilament protein dimers is the first step in heteropolymer assembly. 
[Au: Sentence added to enable addition of a paragraph break. OK?] Antiparallel aggregation of 
these dimers leads to formation of tetramers, and eight laterally associated tetramers form the 
cylindrical unit-length filament (UFL) structure11,12. Annealing of UFLs leads to longitudinal 
elongation of neurofilaments, which is followed by radial compaction to form the final long 
neurofilaments with diameters of 10 nm (Fig. 1)12. 
Post-translational modifications of neurofilaments include addition of O-linked N-
acetylglucosamine (O-GlcNAc) to individual serine and threonine residues, nitration, oxidation, 
ubiquitination and most importantly phosphorylation11, 13. All subunits are phosphorylated on 
their head domain, but only NfM and NfH are extensively phosphorylated on their carboxy-
terminal domains, and this phosphorylation increases the resistance of these subunits to 
proteases14. [Au: Does this edit retain your meaning? Or do you mean that the fact these 
subunits are phosphorylated makes them more resistant to proteases than the other subunits?] 
Under normal conditions, neurofilaments are highly stable within axons, and their turnover is low. 
The filaments form a liquid crystal gel network with in diseases like ALS, Lewy-body-based 
dementia or Parkinson’s disease, neurofilament accumulation [Au: Please clarify what you mean 
by compartmental accumulation - where is this accumulation, and what compartments are 
being referred to?] related to subunit stoichiometry and the degree of phosphorylation14. 
The precise functions of neurofilaments remain unknown, but they are thought to be 
critical for radial growth and stability of axons, thereby enabling effective, high-velocity nerve 
conduction15,16. Several reports indicate that neurofilaments interact with other proteins and 
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organelles, including mitochondria and microtubules11, suggesting that they have important 
functions beyond preserving axonal stability. 
Several mutations identified in the genes that encode neurofilament proteins can lead to 
abnormal neurofilament aggregation and accumulation with the consequence of axonal 
dysfunction and neurodegeneration. For example, mutations in the NEFL gene, which encodes NfL, 
lead to Charcot-Marie-Tooth Neuropathy Type 2E/1F (CMT2E/1F) [Au: Please make clear what the 
two abbreviations mean specifically] disease. Mutations of the genes that encode peripherin 
(PRPH), NfH (NEFH) and NfM (NEFM) have been associated with increased susceptibility to 
amyotrophic lateral sclerosis (ALS) and familial Parkinson disease (PD). Mutations in genes other  
than those that encode neurofilament proteins can have secondary effects on neurofilament 
aggregation; such mutations include those in heat-shock 27-kDa protein 1 in CMT2F, gigaxonin in 
giant axonal neuropathy and superoxide dismutase 1 (SOD1) in ALS11,17. 
 
[H1] Assays to detect soluble neurofilaments 
In the past three decades, impressive advances have been made in the development of sensitive 
immunoassay technologies. With these advances, detection of neurofilaments has improved 
(Fig. 2), [Au: See my suggestion for making Figure 1c a separate Figure 2] moving towards 
evermore clinically useful capabilities. [Au: I have added the previous sentence firstly because I 
felt it was helpful to relate the advances to neurofilament in a general sense at the outset, and 
also because I think it would be nice to have each generation discussed in its own paragraph, but 
breaking the paragraph here left one sentence in the first paragraph, which is not ideal. Addition 
OK?]  
First-generation [Au: Unfortunately, our style does not allow use of italics for emphasis] 
immunoassays were semi-quantitative at best. Immunoblots based on electrophoretic protein 
separation or dot blots were, however, consistent in that they reliably demonstrated the presence 
of neurofilament isoforms in the CSF and blood of patients with a range of diseases10. 
Second-generation sandwich ELISA technology produced the first reliable quantitative data 
that enabled assessment of the prognostic and diagnostic value of NfH and NfL in the CSF in 
human disease2,18-20. Human body fluid compartments that were analysed with this technique 
extended to the interstitial and extracellular fluid21, serum and plasma, amniotic fluid and the 
vitreous body22. Meta-analyses and international validation studies demonstrated that high 
precision could be achieved in expert laboratories, but also highlighted the need for improved 
assay standardization23,24. [Au: Standardization of what? Please clarify]  
8 
 
Third-generation ECL technology led to a substantial improvement in the analytical 
sensitivity4, 5, 25-27. ECL based assays are known to be highly sensitive, exhibit a broad dynamic 
range and require small sample volume, however we found the SiMoA technology to be 126- and 
25-fold more sensitive than ELISA and the ECL assay, respectively, to quantify NfL7. [Au: Is it 
possible to expand on this statement to explain more about the technology, why it improved 
sensitivity and the limitations it still had?]  
Finally, fourth-generation SiMoA technology improved analytical sensitivity to an extent 
that reliable quantification of NfL levels in blood became possible across the range of 
concentrations that are observed in disease and in physiological conditions6-8,28. This cutting-edge 
method is based on single-molecule arrays and the simultaneous counting of singulated capture 
microscopic beads (2.7 µm diameter) carrying sandwich antibody complexes. [Au: Please clarify 
for non-experts what these microbeads are - presumably neurofilament proteins bind to them?] 
The analytical sensitivity is manifold higher than with use of the same antibodies in the ELISA 
format designed for CSF measurements19, and enables reliable measurement of the low NfL 
concentrations in blood samples from young healthy individuals6, 8 so that minor changes in levels 
of this protein that occur in normal ageing or after mild injury [Au: Change from “concussion” to 
mild injury OK?] can be monitored. Close correlation between NfL levels in the serum or plasma 
with levels in the CSF, which has been demonstrated in numerous studies and various neurological 
diseases, allows conclusions about the degree of ongoing neuroaxonal injury to be drawn from 
blood levels without the need to obtain CSF by lumbar puncture4, 8, 29-36. Investigations of NfM 
have been sparse37, but commercial SiMoA kits for detection of NfL and phosphorylated NfH are 
available.  
 
[H1] Neurofilaments in ageing [Au: Edited to fit our character limits for headings and also 
because only ageing is discussed in this section. OK?]  
Normal ageing is associated with neurodegenerative processes that can be detected with various 
markers such as volumetric loss of brain tissue [Au: Here, I think the wording raises the question 
for the reader of why neurofilaments are needed as a marker if neurodegeneration can be 
detected with other markers. I assume the existing markers, such as imaging, are more difficult 
and more costly and the neurofilament could be detected with a simple blood test - correct? If 
so, I think it would be helpful to explain this so that the reader is clear about the need for 
neurofilament.] but also by increased levels of a range of fluid biomarkers comprising 
neurofilaments. The advantage of an easy to access body fluid biomarker, such as neurofilament in 
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the blood is to provide a real-time signal on neuro-axonal damage of the entire CNS, paralleled by 
lower costs and the ability of repeated measurements in a relatively non-invasive manner (Barro 
et al. Brain 2018).  In CSF, the normal upper reference value for NfL levels increases 2.5-fold 
between the ages of 20 years and 50 years, and doubles further by the age of 70 years38. This age-
related increase in levels in the lumbar CSF could be due to reduced CSF turnover39, as a general 
physiological phenomenon39 [Au: Did you mean that reduced CSF turnover is a general 
physiological phenomenon? I have removed on the basis of this, as I felt it was not necessary, 
but if you meant a general physiological phenomenon to be a separate item in the list, please 
clarify] but could also indicate slow, ongoing axonal injury. The latter possibility is supported by 
the finding that CSF levels of NfL in cognitively healthy elderly individuals correlate with 
hippocampal atrophy independently of age and AD biomarkers40. However, a detailed 
understanding of the mechanisms that underlie age-related increases in neurofilament levels is 
lacking. Besides structural damage and loss of neurons, metabolic alterations in the turnover of 
neurofilament proteins might play a role: experimental evidence demonstrates complex changes 
in the expression of mRNA, post-translational mRNA modification  [Au: “post translation” 
removed from here because it did not seem to relate to anything. If it is necessary, please clarify 
what it meant.] and neurofilament protein turnover41. 
A highly significant correlation is also seen between age and NfL blood levels: use of  [Au: 
“fourth generation” removed from here because it implied that there have been four 
generations of SiMoA technology.] SiMoA technology has shown that NfL levels in the blood 
increase by 2.2% per year between the ages of 18 years and 70 years8,42. The strong correlation 
between CSF and blood levels of NfL at the group level suggests that the two measures reflect 
similar physiological processes4, 8, 29-36. [Au: Change from “factors” to “physiological processes” 
OK?] Nevertheless, important to acknowledge is the possibility that degenerative processes in the 
PNS contribute to neurofilament levels in peripheral blood4, 43, 44. 
Important for further development of neurofilaments as a biomarker is to establish 
universal reference values for healthy controls by analysis of samples under standardized and 
controlled conditions in reference laboratories. These reference values would enable correct 
interpretation of levels seen in various pathological conditions, thereby maximizing the potential 
of neurofilaments in the management of [Au: Addition of “the management of” OK?] diseases 
that involve neuroaxonal injury.  
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[H1] Neurofilaments in neurological disease [Au: Edited to fit our character limits for headings. 
OK?]  
 
CSF and blood levels of neurofilament proteins have been measured in various neurological 
disease (Box 1), and evidence has accumulated that they can be clinically useful biomarkers in 
many of these. Below, we discuss the evidence in each of the studied diseases. [Au: I have added 
this paragraph to provide a short introduction to this main section and also to provide an 
opportunity to cite Box 1. Please see my suggestion for converting Figure 2 to Box 1 below.]  
 
[H2] Multiple sclerosis 
Multiple sclerosis (MS) is a chronic disease of presumed autoimmune origin that is, at least 
initially, characterized by episodes of focal inflammation in the brain and spinal cord  that 
predominantly involve the white matter but can involve the grey matter45. Formation of new 
lesions can be visualized with MRI, the only established biomarker of disease activity used in 
routine clinical practice today. However, MRI primarily detects lesions in the white matter, and 
grey matter damage is largely missed with standard imaging techniques46, 47. In addition, MRI does 
not allow selective detection of neuroaxonal degeneration, which seems to be the most important 
determinant of long term disability48-50. Several MRI-based volumetric measures, including analysis 
of cortical thickness, have been used to assess neuronal degeneration, but the specificity and 
sensitivity of these measures at the individual level are limited51. 
Use of second-generation immunoassays to measure NfL, pioneered by Rosengren et 
al.18,52, revealed three key aspects of disease associated with CSF levels of NfL: [Au: Edited for 
clarity about what the relationships are between. OK?] the degree of disability, disease activity, 
and the time since the last relapse in patients with relapsing–remitting MS (RRMS)52. These initial 
findings were replicated and extended by subsequent, larger studies of clinical aspects associated 
with CSF levels of NfL53-56 and NfH26, 54, 57, 58. 
Use of third-generation immunoassays further revealed that CSF levels of NfL reduce as a 
consequence of disease-modifying therapy (DMT). For example, initiation of the high-efficacy DMT 
natalizumab resulted in normalization of CSF NfL levels to those seen in healthy controls within 6–
12 months59, suggesting that NfL can be used to monitor therapeutic efficacy. Similar observations 
were made in placebo-controlled60 and observational61, 62 studies of fingolimod in patients with 
RRMS and in studies of mitoxantrone and rituximab63 and of natalizumab64 in progressive MS. 
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Despite the promising results in MS, a major barrier to widespread adoption of NfL analysis 
in MS research and clinical practice has been the requirement of CSF sampling, but this problem 
has finally been overcome by use of fourth-generation immunoassays. Of particular interest is the 
demonstration that serum levels of NfL can be used to separate not only patients with MS from 
healthy controls, but also patients with MS who have enhancing MRI lesions from patients without 
such lesions8. Furthermore, serum NfL levels in patients with MS have been independently 
associated with disability and relapse status8, Barro et al., Brain 2018, [Au: Please cite the appropriate 
reference(s) to support this statement] and the risk of future relapses and disability worsening is 
higher among patients with high serum levels of NfL than those with lower levels8, Barro et al Brain 2018 . 
[Au: Please cite the appropriate reference(s) to support this statement] Finally, patients with 
ongoing DMT had lower serum NfL concentrations than did untreated patients8. Yet another study 
found that patients who switched from injectable therapies to [Au: Edited because it wasn’t clear 
what injectable therapies are less effective in comparison to until you continued, whereas this 
wording makes clear that fingolimod is more effective than injectables. OK?] fingolimod had 
significantly lower serum NfL levels than when they were on injectables [Au: Lower than levels 
when they were on injectables, or lower than patients who continued on injectables? Please 
clarify] over a 2-year period30. Associations with disease activity and treatment-related reductions 
in serum NfL levels were confirmed by another observational study in which a fourth-generation 
immunoassay was used in a large, independent cohort of patients with RRMS36. Recently, a 
longitucinal observational study demonstrated that patients with increased serum NfL at baseline, 
independently of other clinical and MRI variables, experience significantly more brain and spinal 
cord volume loss over 2 and 5 years of follow-up (Barro et al., Brain, 2018). 
Collectively, the findings described (Table 1) make a strong case for bringing fourth-
generation serum NfL assays from the bench to the clinics in the management of MS. Further 
studies are required to show how these assays can be used for monitoring disease activity and for 
therapeutic decision-making. 
 
 
[H2] Dementias 
Dementia — defined in this context as cognitive disturbances that are severe enough to interfere 
with activities of daily living — can be caused by several different neurodegenerative disorders, of 
which Alzheimer disease (AD) is the most prevalent, frontotemporal dementia (FTD) is the second-
most prevalent among people aged <60 years, and dementia with Lewy bodies (DLB) is the 
second-most prevalent among patients aged >60 years. [Au: Edited to define “older” on the basis 
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of the definition of “younger” in the previous sentence. OK?] Currently, clinical diagnosis of the 
different types of dementia relies largely on documenting cognitive decline or on post-mortem 
evaluation. However, it is becoming clear that early brain damage occurs decades before the onset 
of clinical symptoms. This observation opens a window of opportunity for secondary prevention 
and suggests the value of [Au: Change of wording OK?] a shift from using clinical hallmarks for 
diagnosis to monitoring of biological measures that reflect ongoing pathological processes. Several 
studies have addressed the question of whether neurofilaments can provide such a biological 
measure (Table 2). [Au: Sentence added to enable citation of Table 2. OK?]  
An early study in 1999 demonstrated a mild increase in CSF levels of NfL in AD, and 
substantially higher levels in FTD66. These findings were confirmed in a subsequent study that also 
showed that the increase in CSF levels of NfL in AD is seen only in patients with late-onset disease, 
[Au: Edit to avoid referring to patients as “cases”] whereas NfL levels are not significantly 
different from normal controls [Au: Edited to specify controls - correct?] in patients with early 
onset AD67. 
Subsequent meta-analyses of findings obtained with second-generation immunoassays 
consistently demonstrated that CSF levels of NfL are increased in the mild cognitive impairment 
and dementia stages of AD23, 68 and are independent of Aβ load68,69. [Au: Edited for clarity. OK?] 
The diagnostic specificity of NfL levels was lower than the hallmark AD biomarkers of Aβ1–42 levels, 
[Au: OK?] Aβ1–42:Aβ1–40 ratio and phosphorylated tau levels68,70. Nevertheless, evidence indicates 
that NfL levels correlate with and are predictive of brain atrophy and worsening of cognition 
independently from  Aβ pathology69, 71. Moreover, NfL levels in the blood have some predictive 
value for progression to AD dementia in patients with subjective memory complaints42, so the 
potential for use of NfL levels in combination with clinical evaluation and other biomarkers to 
detect the earliest stage of the disease should be assessed. Furthermore, the greatest value of NfL 
in AD dementia could be in monitoring responses to treatment, as in MS, as reductions in plasma 
NfL [Au: Please explain what was observed - presumably NfL levels decreased?] were observed 
in animal models of AD when treated with a BACE-inhibitor31. 
Measurement of NfL levels is also likely to be of value in the diagnosis of FTD, in which 
CSF23,67  and serum35,75 levels of NfL [Au: CSF levels of NfL correct?] are high and approach those 
observed in ALS (see Amyotrophic lateral sclerosis section below). Indeed, among the chronic 
dementias, the highest CSF NfL concentrations are observed in FTD and vascular dementia, 
followed by AD23, 72. Among patients with FTD, CSF levels of NfL are higher in those with TAR DNA-
binding protein 43 (TDP-43) inclusions than in those with tau pathology (confirmed by genetic 
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testing or post-mortem evaluation)73. Moreover, CSF levels of NfL increased when symptoms 
developed in patients with genetic FTD, and these levels were inversely correlated with survival35. 
Several studies have confirmed a strong relationship between CSF and serum levels of NfL and the 
time to death in patients with FTD35,73.  
The results of fourth-generation immunoassays74 for detection of neurofilaments reflect 
neuroaxonal damage in neurodegenerative dementias, including FTD75, familial and sporadic AD42, 
76 and atypical parkinsonian disorders77. In sporadic AD, plasma NfL concentrations are already 
increased in the mild cognitive impairment stage, and correlate with cognitive, biochemical and 
imaging hallmarks of the disease42. In familial AD, blood NfL concentrations start to increase 
~10 years before the expected onset76. 
Very high CSF and blood levels of NfL [Au: This is a little confusing, because CJD has not 
been mentioned earlier in the section, and earlier in the section, it’s stated that the highest 
levels of NfL are seen in FTD among the dementias. This conflict either needs to be resolved, or 
the discussion of CJD needs to be omitted. Also, does “highest” here mean within dementias, or 
the highest in any condition?] have been observed in patients with sporadic and familial 
Creutzfeldt–Jakob disease. In this condition, CSF levels of NfL were increased before symptom 
onset, and the sensitivity and specificity of serum NfL concentration for diagnosis of Creutzfeldt –
Jakob disease [Au: Addition correct, to ensure it’s clear what the sensitivity and specificity relate 
to?] were 100% and 85.5%, respectively78. Elevated serum levels of NfL have also been described 
in patients with primary progressive aphasia79; [Au: Please cite the appriopriate reference(s) to 
support the previous statement] higher levels were identified in patients with the non-fluent or 
agrammatic and semantic variants than in those with the logopenic variant. NfL levels correlated 
with clinical progression and brain volume loss in all patients with primary progressive aphasias79. 
[Au: Does the last sentence relate to all three variants, or only the non-fluent and semantic 
variants? Please clarify.]  
 
[H2] Stroke 
Most existing data on neurofilaments in stroke are CSF measurements in subarachnoid 
haemorrhage (SAH). Studies have shown that NfH and NfL levels are higher among patients with 
aneurysmal SAH than among healthy controls or patients free of neurological disease80-82. [Au: 
Please define the controls more specifically - were they healthy?] The exact causes of 
neurofilament elevation in SAH in the absence of associated focal lesions (parenchymal 
haematoma or ischaemia owing to vasospasm) are not entirely clear, but are presumably 
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attributable to diffuse neuroaxonal injury or iatrogenic following for eaxample placement of an 
external ventricular drain. [Au: Please clarify what you mean by “neurosurgical procedures”] 
Regardless, evidence suggests that neurofilament levels consistently correlate with the clinical 
severity and extent of morphological brain damage80, 81.  
The ability to analyse neurofilament light levels in blood samples with fourth-generation 
immunoassays has facilitated the study of this marker in stroke in which a lumbar puncture is 
usually not indicated. [Au: Please clarify. Do you mean that lumbar puncture is not indicated in 
some subtypes, or do you mean that lumbar puncture is not indicated in stroke generally? And 
by “not indicated”, do you mean it is contra-indicated, or there is just no reason to do it?] This 
approach has been used to show that serum levels of NfL are higher among patients with 
spontaneous cervical artery dissection who had an ischaemic stroke than among those with 
transient ischaemic attacks or isolated local symptoms83. [Au: Change to “isolated” OK?] Similarly, 
serum NfL concentration was found to be increased in patients with a single, recent, small 
subcortical infarct compared with concentration in age-matched and sex-matched healthy 
controls84. In the same study, assessment of the temporal dynamics of NfL at 3 months and 
15 months after stroke revealed especially high levels in patients with new, clinically silent brain 
lesions related to small vessel disease detected with MRI during follow-up, suggesting that NfL 
levels indicate active small vessel disease. Interestingly, serum NfL levels increased during the first 
few days after stroke onset and remained elevated in a follow-up assessment at 3 months. 
Comparable findings of neurofilament dynamics have been reported in other studies5, 83, 85. 
Prolonged release of NfL into the blood after acute neuronal injury might be caused by persistent 
blood–brain barrier breakdown, but ongoing post-ischaemic immunological or inflammatory 
processes could also explain these findings. 
 
[H2] Traumatic brain injury 
Mild traumatic brain injury (TBI), also called concussion, is caused by non-penetrating head trauma 
and is increasingly recognized as a major health problem86. Most patients with mild TBI recover 
within hours to days, but a percentage have symptoms for weeks to months after the head 
impact, a condition called post-concussive syndrome. Furthermore, an unknown proportion of 
people who are exposed to repeated concussions, primarily contact sports athletes such as boxers 
and American football players and soldiers who are exposed to explosive blasts, develop a chronic 
neurodegenerative disease called chronic traumatic encephalopathy (CTE)87, previously known as 
dementia pugilistica88. 
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Mild TBI and post-concussive syndrome are vaguely defined clinical entities and their 
diagnosis is based only on the presence of one or several unspecific symptoms (such as loss of 
consciousness, dizziness, headache and poor concentration), causing a major issue in research, 
clinical management and drug development in this field86. Consequently, sensitive biomarkers are 
needed to identify and grade neuronal injury in individuals with mild TBI and post-concussive 
syndrome. Furthermore, biomarkers that enable grading of severity of neuronal injury after a mild 
TBI might be important as objective tools for guiding sports physicians with return-to-play 
decisions for their athletes.  
Studies of contact sports athletes with mild TBI show that CSF levels of NfL increase more 
than levels of tau, suggesting that minor head injuries affect long myelinated white-matter axons 
more than they affect shorter cortical axons89,90. In severe TBI, fourth-generation NfL 
immunoassays6 have demonstrated a marked increase in blood NfL levels that also predicted 
clinical outcome91, thereby confirming earlier findings from third-generation immunoassay studies 
of CSF and blood samples92. Interestingly, marked increases in blood NfL levels have been 
detected in amateur boxers after a bout; higher NfL levels were seen in boxers who had received 
more head impacts, and levels approached normalization after 3 months of rest from boxing93. 
Similarly, blood levels of NfL were found to increase during the course of a season in American 
football players94. Taken together, these results (Table 3) support the idea that the blood level of 
NfL is a sensitive indicator of axonal injury after mild TBI and is a promising candidate for clinical 
application and contact sports medicine. 
 
[H2] Amyotrophic lateral sclerosis  
Motor neuron diseases are neurodegenerative disorders characterized by degeneration of the 
upper and lower motor neurons, and the most common form is ALS95. Given that axonal 
impairment can be seen early in the disease, measurement of neurofilaments in the CSF of 
patients with ALS was an obvious and straightforward experiment and led to the observation that 
NfL levels are increased in this condition18,96,97. 
Several independent studies have confirmed that neurofilament levels are significantly 
elevated in patients with ALS compared with several other disorders (Table 4); the largest 
prospective study included 455 patients34, 98-103. Diagnostic sensitivities and specificities were up to 
~80%. Higher levels were also associated with faster disease progression. Increases in NfL and NfH 
levels were also observed in the early clinical phase of patients with genetic ALS and in patients 
with sporadic ALS33, 104-107. The first clinical sign of the disease seems to be associated with a 
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massive increase of neurofilament levels in the CSF33, and a corresponding increase in NfL levels 
has been observed in the blood33. Furthermore, increased levels of blood NfH have been seen in 
patients with sporadic ALS 100, 102, 108.The difference in dynamics of higher NfL levels if compared to 
NfH levels in ALS and controls may partly be explained by earlier assay sensitivity issues. A new 
hypothesis, adaptive protein stoichiometry, suggests that the neurodegenerative process itself 
alters the quantitative relationship of neurofilament subunits. This leads to a relative over 
expression of NfL compared to NfM and NfH in order to minimise ATP requirements for subunit 
translation in the motorneuron [Zucchi et al. Journal Neurochemistry, 2018]. [Au: Edited for 
clarity. OK?]  
Although helpful for diagnostic purposes, the reason for the very high CSF levels of 
neurofilaments in ALS is still not entirely clear, even under the assumption that neurofilament 
levels reflect neuroaxonal damage. One small study showed a correlation of NfL levels with axonal 
impairment assessed with diffusion tensor imaging (DTI)109, [Au: Edited to streamline. OK?] but 
this correlation was not seen in a similar study that included 75 patients101. [Au: Edited to clarify 
and simplify. Is there a significance to the number of patients in the second study - is it much 
larger than the number in the first study? Please make this clear, because I think it is important 
to indicate to the reader which of these two studies is likely to be more reliable.] NfL 
concentrations in the blood seem to be stable at a very high level during follow-up of patients with 
ALS, whereas DTI values increase34, 79; only [Au: Addition of “only” OK?] a slight increase in blood 
levels of NfH has been described99. One mechanistic explanation is based on evidence that TDP-43, 
the major neuropathological hallmark of ALS, directly interacts with neurofilament production and 
causes [Au: This wording suggests that the protein causes the release. Do you mean the 
aggregation of TDP-43 causes the release, or another aspect of TDP-43 function/pathology?] the 
sudden and massive release of neurofilaments in ALS110. More prospective studies of 
neurofilament levels in ALS, especially in the blood, are needed. [Au: Please expand on this 
sentence to say why they are needed - to determine the mechanisms, or for translation of the 
findings to clinical use?]  
 
[H2] Parkinson disease 
Although Parkinson disease (PD) is one of the most common neurodegenerative disorders, no 
validated neurochemical biomarkers are currently available to aid clinical diagnosis. In PD and 
other synucleinopathies, α-synuclein is the main component of [Au: OK?] neuronal inclusions. 
Many studies have been performed to assess whether α-synuclein in the CSF could be an effective 
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biomarker of PD; ELISA has been used in most of these studies, which have produced 
contradictory results112,113. [Au: Sentence edited for clarity. OK?]  
In 1998, NfL was first investigated in the CSF of 49 patients [Au: Number of patients added 
here. OK?] undergoing differential diagnosis for a Parkinsonian syndrome, including patients with 
atypical parkinsonian syndromes such as progressive supranuclear palsy (PSP) and multiple system 
atrophy (MSA). These investigations demonstrated increased CSF NfL levels in PSP and MSA 
compared with the PD group patients114. [Au: Correct that the levels were increased in all of 
these patients?] This increase in PSP and MSA versus PD was also seen for NfH115. In a larger study 
that included >450 patients with PSP, MSA or PD, almost no overlap was seen between CSF levels 
of NfL in patients with atypical parkinsonian disease and those with PD; NfL levels were increased 
mainly in the atypical disorders116. The finding was validated in an independent cohort117. 
In a study published in 2016, high levels of NfL were observed in blood of patients with PSP, 
and this difference persisted at one year follow-up. [Au: Correct that the follow-up was after 
treatment? How long was the follow-up period? How were they treated? Please add more detail 
so that findings are clearer] Patients with higher NfL levels had more severe neurological, 
functional, and neuropsychological deterioration over 1 year. Higher baseline NfL predicted 
greater whole-brain and superior cerebellar peduncle volume loss118. On the basis of these 
findings, the investigators concluded that NfL could be used not only to aid diagnosis, but also to 
monitor pharmacodynamic effects, especially in clinical trials. The findings of this study were also 
validated in three independent cohorts, leading to the suggestion that NfL could be used in both 
primary care and specialized clinics77. 
 
[H2] Huntington disease [Au: I didn’t see any reason to group HD and bipolar disorder together.]  
Huntington disease (HD) is a progressive neurodegenerative disorder caused by CAG repeat 
expansions in the HTT gene, leading to the formation of mutant huntingtin (mHTT). No proven 
disease-modifying treatments yet exist119. The slow and insidious progression of 
neurodegeneration in HD has made it challenging to detect disease-related changes in the levels 
of neurofilament proteins in the blood120. However, increased CSF levels of NfL have been 
demonstrated in patients with HD121, 122, and fourth-generation technology has revealed a strong 
relationship between plasma levels of NfL, HD onset and subsequent progression of 
neurodegeneration119. If confirmed, blood NfL levels could be included as a secondary outcome 
measure in future clinical trials in HD.  
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[H2] Bipolar disorder [Au: We don’t generally cover psychiatric conditions, but I do feel it is 
interesting to include this because the fact that there are some changes in a disease associated 
with some degeneration reinforces the association of the marker with neuronal injury. 
However, I have suggested some changes to wording to emphasize the aspects that will 
probably be of most interest to our audience. Please check that you are happy with these 
changes.]  
Some evidence suggests that neurodegeneration and neuroaxonal injury can be associated with 
some subtypes of bipolar disorder123. Although these aspects are not prominent features of the 
condition, CSF levels of NfL were slightly increased in a subset of patients, particularly those who 
are treated with atypical antipsychotics124, presumably reflecting a not yet fully understood 
disease-associated or treatment-associated effect. [Au: Addition made to emphasize the focus on 
the biological/mechanistic aspects. OK?] However, no clear relationship was seen between NfL 
levels and clinical outcomes, such as manic or hypomanic and depressive episodes (cross-sectional 
data), suicide attempts, psychotic symptoms or inpatient care125. Although the current evidence 
for detection of neuroaxonal injury in bipolar disorder by measuring neurofilaments is limited, the 
available results warrant longitudinal studies of well-characterized patients to examine how 
neurofilament concentrations change over time in relation to disease activity and phase 
(depression and mania) and whether neurofilaments can indicate adverse effects of treatments. 
Fourth-generation measurement technology will facilitate such studies by enabling measurements 
to be taken from blood samples.  
 
 
[H1] Conclusions and future aspects [Au: The last section of all our Reviews must contain the 
word “conclusions”. Change of heading OK?]  
In summary, highly sensitive neurofilament measurements have the potential to fill a gap in the 
assessment of neuroaxonal damage in various neurological disorders. For the first time, this 
approach provides a sensitive assessment of the consequences of brain tissue damage with only a 
blood sample, an important advance to aid research and towards use of the assays in clinical 
practice. [Au: Edited to give the importance of the advance a little more weight?] In relation to 
clinical trials, the reviewed characteristics of neurofilaments, especially of NfL, make these 
proteins optimal candidates as markers of outcome in phase II trials in neurological disorders. 
Definitive phase III trials must use clinical endpoints (clinical events with a clear effect on the 
duration or quality of life) to confirm a clinical benefit, but the aim of phase II trials is to identify 
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drugs with sufficient activity to continue to phase III, so earlier end points are preferable. [Au: 
Information about trial end points edited to improve flow. OK?]  [Au: The previous sentence has 
been removed, as this passage felt a bit repetitive. OK?] 
To validate neurofilament measurements as phase II trial end points, two additional 
properties must be verified: a correlation with the clinical end points used in phase III trials, and an 
ability to detect a treatment effect. To verify these properties, a promising approach is 
retrospective analysis of data from randomized clinical trials in which blood samples suitable for 
measurement of neurofilaments have been collected. Comparison of neurofilament levels 
between subgroups of patients enrolled in the trials would determine whether the drug tested 
had an effect on the neurofilament biomarker. Moreover, neurofilament levels and their 
stoichiometry could be correlated with all the other relevant clinical and para-clinical measures 
collected in the trial. 
The main factors limiting application of neurofilament measurements to disease 
monitoring individuals are the lack of normal values of neurofilament across all age groups, a 
detailed understanding of how comorbidities affect blood neurofilament measurements, and the 
need for thorough multicentre analytical assay validation to achieve standardized and reliable 
measurements across different sites. In light of the effect of ageing on neurofilament levels, 
generation of normative data in large collections of controls is a priority. Co-ordinated multicentre 
research activities are already ongoing to tackle these obstacles.  
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Figure 1 | Structure, assembly and release of neurofilaments. [Au: The figure needs an overall 
title. Suggestion OK?] a | Domain structure and post-translational modifications of neurofilament 
subunits11. Neurofilament light chain (NfL), neurofilament medium chain (NfM), neurofilament 
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heavy chain (NfH), α-internexin and peripherin are the subunits of neurofilaments in the mature 
nervous system. All neurofilament subunits include a conserved α-helical rod domain that 
comprises several coiled–coils, and variable amino-terminal globular head regions and carboxy-
terminal tail domains. NfM and NfH subunits are unique among the intermediate filament proteins 
in that they have long carboxy-terminal domains with multiple lys–ser–pro repeats that are heavily 
phosphorylated. Phosphorylation and O-linked glycosylation sites on neurofilament subunits are 
shown. E segment, glutamic-acid-rich segment; E1, glutamic-acid rich segment 1; E2, glutamic-
acid-rich segment 2. [Au: We will use the three-letter amino acid codes in the figure, so the one-
letter codes do not need to be in the legend.] b | Neurofilament assembly. Neurofilament protein 
monomers form parallel coiled-coil heterodimers11. Two dimers form staggered antiparallel 
tetramers through interactions between coil domains 1a, 1b and 2a12. The lateral association of 
eight tetramers results in formation of cylindrical structures known as unit-length filaments that 
have a diameter of ~16 nm and a length of ~60 nm. Gradual end-to-end annealing of these unit-
length filaments results in filament elongation, which is followed by radial compaction to form the 
mature, long neurofilament polymer with a diameter of ~10 nm. Tail domains of NfM and NfH 
radiate outwards from the filament core because of the extensive negative charges from large 
numbers of glutamic acid and phosphorylated serine and threonine residues. 
[Au: I suggest that part c is a separate figure, because it deals with a slightly different aspect to 
the structure, and this avoids adding to what is already a very long figure legend.]  
Figure 2 | Neurofilament release after axonal damage. When an axon is damaged, cytoskeletal 
proteins, including neurofilaments, are released into the extracellular space and subsequently into 
the CSF and, at lower concentrations, into the blood. First-generation (immunoblots) and second-
generation (ELISA) immunoassays can typically detect neurofilament in the CSF. Third-generation 
(electrochemiluminescence) and, in particular, fourth-generation (Single molecue array) 
immunoassays can reliably measure blood levels of neurofilament light which was not possible 
from the blood with ELISA. 
 
[Au: I think the information in your figure 2 would be better presented in a text box because it is 
really just text. I have suggested a format for this below.]  
 
Box 1 | Relevance of neurofilaments to neurological disorders 
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Neurofilaments have been studied in several neurological disorders, and in many, good evidence 
indicates their diagnostic and prognostic value and/or their use for monitoring treatment 
responses. The disorders reviewed here are: 
- Multiple sclerosis 
- Dementia 
- Stroke 
- Traumatic brain injury 
- Amyotrophic lateral sclerosis 
- Parkinson disease 
- Huntington disease 
- Bipolar disorder (limited evidence for clinical utility). 
In addition, neurofilaments could be of relevance in many other neurological disorders, but their 
association with these disorders has not been studied. Such disorders include: 
- Epilepsy 
- Encephalitis 
- Meningitis 
- Hypoxic brain injury 
- Optic neuropathies 
- Intracranial pressure 
- Neurotoxicity 
- Peripheral neuropathies including Guillain-Barré Syndrome, CIDP and CMT. 
 
